Results per Page:
When on-target misses the mark: Lessons from HIV immunogens
From the McGuire Lab, Vaccine and Infectious Disease Division
Dr. Peter Gilbert receives Marvin Zelen Leadership Award in Statistical Science
Award recognizes leadership in HIV vaccine trial development, analysis
Transient transfection to make vaccines: cutting corners, or taking the express lane?
From The Kublin and Corey Labs, Vaccine and Infectious Disease Division
‘Action and progress link our globe’
HVTN’s Dr. Daniel Driffin focused on hope in remarks at White House World AIDS Day event
First in-human HIV vaccine to induce virus-specific neutralizing antibodies
From the McElrath Lab, Vaccine and Infectious Disease and Clinical Research Divisions
Vaccine trial volunteer works to empower her community, end HIV
Community Advisory Board member Tasia Baldwin helps raise awareness of the ongoing HIV epidemic and how individuals can get involved in research aimed at ending it
A shot for every limb: how splitting up the HIV vaccine may increase immunogenicity
HIV Vaccine Trials Network (HVTN)
How we measure success matters when evaluating HIV therapies
From Dr. Dan Reeves, Vaccine and Infectious Disease Division
Researchers identify strong T-cell response in first-in-human nanoparticle HIV vaccine
Study result moves scientists closer to developing elusive HIV vaccine
Is the microbiome a springboard or barrier to effective vaccination?
From the Kublin Lab, Vaccine and Infectious Disease Division
Mosaic HIV immunogens boost the breadth of vaccine immune responses
From the Gilbert and McElrath Labs, Vaccine and Infectious Disease Division
On World AIDS Day, a broad view of continuing work
Teams of Fred Hutch scientists test vaccines, treatments, new strategies
Fauci visits Fred Hutch, discusses pandemics, vaccines and scientific misinformation
NIAID director’s determined spirit recognized with honorary Hutch Award
Optimizing antigen design may improve HIV vaccine efforts
From the Pancera, McElrath and Stamatatos labs, Vaccine and Infectious Disease and Clinical Research Divisions
Test of a new 'germline-targeting' HIV vaccine prepares to launch
Vaccine’s unique protein designed to start process of building powerful antibodies against AIDS virus
IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology
Phase 1 trial aims to build on response seen in proof-of-concept trial